Trk NLF Neuroblastoma Cell Lines
Immortalized cell lines (NLF) that express Trk-A or Trk-B. Control Trk-NULL NLF cell line also available.
Highlights
- NLF Neuroblastoma cell lines expressing Trk-A or Trk-B
- NLF Trk-NULL cell line also available
Neuroblastoma (NB) is a tumor of the peripheral nervous system in children, and several receptor tyrosine kinase (RTK) genes have been implicated in malignant transformation or progression of these tumors, including ALK, NTRKs, RET, EGFR and IGFR. The Trk family of neurotrophin receptors (TrkA encoded by NTRK1, TrkB encoded by NTRK2, TrkC encoded by NTRK3) have been shown to play critical roles in regulating both favorable and unfavorable clinical behavior in NBs. TrkA is the receptor for nerve growth factor (NGF), and high TrkA expression is associated with clinically and biologically favorable tumors that have a propensity to undergo spontaneous regression or differentiation. TrkB is the cognate receptor for brain-derived neurotrophic factor (BDNF), and high expression of TrkB plus BDNF is found in the majority of high-risk NBs, especially those with MYCN amplification.
From the laboratory of Garrett M. Brodeur, MD, Children's Hospital of Philadelphia.
Immortalized cell lines (NLF) that express Trk-A or Trk-B. Control Trk-NULL NLF cell line also available.
Highlights
- NLF Neuroblastoma cell lines expressing Trk-A or Trk-B
- NLF Trk-NULL cell line also available
Neuroblastoma (NB) is a tumor of the peripheral nervous system in children, and several receptor tyrosine kinase (RTK) genes have been implicated in malignant transformation or progression of these tumors, including ALK, NTRKs, RET, EGFR and IGFR. The Trk family of neurotrophin receptors (TrkA encoded by NTRK1, TrkB encoded by NTRK2, TrkC encoded by NTRK3) have been shown to play critical roles in regulating both favorable and unfavorable clinical behavior in NBs. TrkA is the receptor for nerve growth factor (NGF), and high TrkA expression is associated with clinically and biologically favorable tumors that have a propensity to undergo spontaneous regression or differentiation. TrkB is the cognate receptor for brain-derived neurotrophic factor (BDNF), and high expression of TrkB plus BDNF is found in the majority of high-risk NBs, especially those with MYCN amplification.
From the laboratory of Garrett M. Brodeur, MD, Children's Hospital of Philadelphia.
| Catalog Number | Product | DataSheet | Size | AVAILABILITY | Price | Qty |
|---|
| Product Type: | Cell Line |
| Cell Type: | Epithelial |
| Accession ID: | Q16620 |
| Organism: | Human |
| Source: | Neuroblastoma |
| Morphology: | Flat, adherent |
| Biosafety Level: | BSL-2 |
| Subculturing: | Versene treatment |
| Growth Conditions: | RPMI-1640, 10% FBS, 0.3mg/mL G418 (for Trk-A and Trk-B cell lines) |
| Cryopreservation: | 5% DMSO 95% FBS |
| Comments: | 18-24 hr doubling time |
| Storage: | Liquid nitrogen |
| Shipped: | Dry Ice |
- Iyer R, Wehrmann L, Golden RL, Naraparaju K, Croucher JL, MacFarland SP, Guan P, Kolla V, Wei G, Cam N, Li G, Hornby Z, Brodeur GM. Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model. Cancer Lett. 2016 Mar 28;372(2):179-86.
- Iyer R, Croucher JL, Chorny M, Mangino JL, Alferiev IS, Levy RJ, Kolla V, Brodeur GM. Nanoparticle delivery of an SN38 conjugate is more effective than irinotecan in a mouse model of neuroblastoma. Cancer Lett. 2015 May 1;360(2):205-12.
If you publish research with this product, please let us know so we can cite your paper.
